<DOC>
	<DOC>NCT00099957</DOC>
	<brief_summary>This study was not conducted in the United States. Many people with type 2 diabetes also have high cholesterol levels. The purpose of this study was to evaluate the effects of vildagliptin, an unapproved drug, on blood lipid measures such as triglycerides and cholesterol in people with type 2 diabetes.</brief_summary>
	<brief_title>A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Blood glucose criteria must be met Genetic markers associated with increased risk of cardiovascular disease Not currently on drug therapy for type 2 diabetes Body mass index (BMI) in the range 2540 Pregnancy or lactation Type 1 diabetes High cholesterol as defined by the protocol Evidence of serious diabetic complications Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
</DOC>